Incisionless surgery sounds like sci-fi until you meet Petal Surgical. Founded in 2021, this Redwood City startup just dropped a $10M Series A, stepping out of stealth like a heavyweight contender ready to swing. Co-led by K50 Ventures and TSVC, with backing from Draper Associates, ShangBay Capital, and individual legends like Dr. Frederic H. Moll, Eliot Horowitz, and Dr. Tony Chou, this one reads like a Silicon Valley mixtape of precision, pedigree, and purpose.
Founder & CEO Prash Chopra didn’t start this journey in a boardroom. It began with loss. His father passed at 52 from surgical complications, the kind of pain that reshapes purpose. Chopra, a former engineer at Intuitive Surgical, decided the future of surgery shouldn’t involve scalpels, scars, or the roulette wheel of human error. Alongside neurosurgeons Dr. Bowen Jiang and Dr. Nicholas Theodore, and with Rony Abovitz, the mind behind Mako Surgical and Magic Leap, as co-founding advisor, Petal Surgical is betting on sound waves, not steel.
Their weapon of choice? Acoustic liquefaction. It’s histotripsy reimagined, using high-intensity focused ultrasound to liquefy targeted tissue with zero incisions, heat, or toxicity. Think of it as turning surgery into pure physics. Target, treat, remove, the body does the rest. No knives. No radiation. No scars. Just precision guided by robotics, AI, and a vision that borders on alchemy.
This isn’t about tinkering with tech for the sake of cool. It’s about addressing the brutal math of modern medicine: 2 billion people lack access to safe surgery. 4.2 million die every year from surgical complications. Roughly 50% of surgical costs go to fixing what went wrong. Petal’s approach could rewrite those numbers entirely, not by cutting deeper, but by cutting out.
With $20 million raised to date, Petal’s next moves are clinical validation, regulatory milestones, and scaling their universal surgical platform, or as Chopra calls it, the “Harry Potter wand” for surgery. From liver tumors to cardiovascular blockages, uterine fibroids to pancreatic cancer, they’re building a single platform with the power to treat dozens of conditions.
When Ryan Bloomer of K50 Ventures calls this their third investment since 2021, that’s not luck, that’s conviction. Eugene Zhang of TSVC saw the same spark he once saw in Zoom. Because every now and then, a startup doesn’t just innovate, it redefines what “possible” sounds like.
